BioCryst Pharmaceuticals has divested the European rights to its hereditary angioedema treatment Orladeyo to Italy-based Neopharmed Gentili in a $250 million transaction. The deal marks Neopharmed Gentili’s entry into the rare disease space and allows BioCryst to focus on other markets for its rare disease portfolio.